Atria Investments Inc lessened its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 1.0% in the third quarter, ...
Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...
GlobalData on MSN3d
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART HytruloZai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
On Tuesday, Wolfe Research upgraded argenx SE (NASDAQ: ARGX) stock from Peerperform to Outperform with a price target of $697.00. The firm anticipates a positive trajectory for the company through ...
Zacks.com on MSN10d
Why Argenx (ARGX) Might be Well Poised for a SurgeArgenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...
(NASDAQ:ARGX – Get Free Report) was downgraded by investment analysts at Baird R W from a “strong-buy” rating to a “hold” ...
Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...
Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting catalysts in favor of Argenx – aside from myositis and ...
On Tuesday, Wolfe Research upgraded argenx SE (NASDAQ: ARGX) stock from Peerperform to Outperform with a price target of $697.00. The firm anticipates a positive trajectory for the company through ...
Q3 2024 Earnings Call Transcript October 31, 2024 Operator: Good morning. My name is Rob and I will be your conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback